GeoVax Labs Inc - Company Profile
Powered by 
All the data and insights you need on GeoVax Labs Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date GeoVax Labs Inc Strategy Report
- Understand GeoVax Labs Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.
Headquarters
United States of America
Address
1900 Lake Park Drive, Suite 380, Smyrna, Georgia, 30080
Website
www.geovax.com
Telephone
1 678 3847220
No of Employees
17
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GOVX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-85.2%
(2022 vs 2021)
Market Cap*
$3.3M
Net Profit Margin (2021)
XYZ
-257.0%
(2022 vs 2021)
* As of and is in US$
GeoVax Labs Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Product Pipeline: |
| HPV-related cancers |
| Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into an agreement with Advanced Bioscience Laboratories, Inc to support current good manufacturing practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1. |
| 2023 | Contracts/Agreements | In February, the company announced its collaboration with EmVenio to expand Phase 2 Covid-19 Booster Vacciene Clinical Trial. |
| 2023 | Official Trials/Tests | In February, the company expanded Gedeptin clinical research for head and neck cancers. |
Competitor Comparison
| Key Parameters | GeoVax Labs Inc | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | France |
| City | Smyrna | New Brunswick | Kenilworth | New York | Paris |
| State/Province | Georgia | New Jersey | New Jersey | New York | Ile-de-France |
| No. of Employees | 17 | 131,900 | 72,000 | 88,000 | 87,994 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David A. Dodd | Chairman; Chief Executive Officer; President | Executive Board | 2018 | 73 |
| Mark W. Reynolds, CPA | Chief Financial Officer; Corporate Secretary | Senior Management | 2006 | 61 |
| Kelly T. McKee, M.D. | Chief Medical Officer | Senior Management | 2022 | 73 |
| Mark J. Newman, Ph.D. | Chief Scientific Officer | Senior Management | 2020 | 68 |
| Harriet L. Robinson, Ph.D. | Chief Scientific Officer - Emeritus, GeoVax | Senior Management | 2007 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer